Form 4: Nuvalent's Chief Medical Officer, Christopher Turner, Reports Stock Transactions

Christopher Turner, Chief Medical Officer of Nuvalent, Inc., reports the acquisition and disposition of Class A Common Stock and stock options on January 6, 2025, including sales to cover tax obligations.

Summary

• On January 6, 2025, Christopher Turner, the Chief Medical Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock.
• Turner acquired 18,750 shares of Class A Common Stock through restricted stock units (RSUs) that vest in three equal annual installments starting January 6, 2025.
• He also sold 1,152 shares at an average price of $78.28, 691 shares at an average price of $79.33, and 2,173 shares at an average price of $80.54.
• These sales were executed under a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations related to the vesting of previously granted equity awards.
• Turner also acquired options to purchase 37,500 shares of Class A Common Stock at an exercise price of $78.09, vesting monthly over four years from January 6, 2025.
• Following these transactions, Turner directly owns 62,547 shares of Class A Common Stock and options to purchase 37,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions include both acquisition of shares through RSUs and options, and sales to cover tax obligations. The sales are pre-planned and don't necessarily reflect a negative outlook.

Positives

• The acquisition of 18,750 shares through RSUs indicates continued alignment with the company's long-term success.
• The grant of options to purchase 37,500 shares further incentivizes the executive.

Future Outlook

The reporting person's future transactions may be influenced by the Rule 10b5-1 plan.

Industry Context

Insider transactions are routinely monitored to gauge executive sentiment and potential future performance of the company. Sales to cover tax obligations are common and don't necessarily indicate a negative outlook.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to align management interests with shareholder value, a common practice among publicly traded biotech companies like Amgen, Gilead Sciences, and Regeneron.
• Rule 10b5-1 plans are a standard tool used by executives to manage their stock sales in compliance with insider trading regulations, similar to practices seen at companies like Pfizer and Merck.
• The vesting schedules for RSUs and stock options are typical, with vesting periods of three to four years being common in the industry, aligning with long-term performance goals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates